Combination of electroporation delivered metabolic modulators with low-dose chemotherapy in osteosarcoma

dc.contributor.authorGill, Kheshwant S.
dc.contributor.authorFernandes, Philana
dc.contributor.authorBird, Brian
dc.contributor.authorSoden, Declan M.
dc.contributor.authorForde, Patrick F.
dc.contributor.funderTeva Pharmaceutical Industries
dc.contributor.funderBreakthrough Cancer Research
dc.date.accessioned2018-09-27T12:08:25Z
dc.date.available2018-09-27T12:08:25Z
dc.date.issued2018
dc.description.abstractBackground: Osteosarcoma accounts for roughly 60% of all malignant bone tumors in children and young adults. The five-year survival rate for localized tumors after surgery and chemotherapy is approximately 70% whilst it drastically reduces to 15–30% in metastatic cases. Metabolic modulation is known to increase sensitivity of cancers to chemotherapy. A novel treatment strategy in Osteosarcoma is needed to battle this devastating malady. Results: Electroporation-delivered metabolic modulators were more effective in halting the cell cycle of Osteosarcoma cells and this negatively affects their ability to recover and proliferate, as shown in colony formation assays. Electroporation-delivered metabolic modulators increase the sensitivity of Osteosarcoma cells to chemotherapy and this combination reduces their survivability. Conclusion: This novel treatment approach highlights the efficacy of electroporation in the delivery of metabolic modulators in Osteosarcoma cells, and increased sensitivity to chemotherapy allowing for a lower dose to be therapeutic. Methods: Metabolic modulations of two Osteosarcoma cell lines were performed with clinically available modulators delivered using electroporation, and its combination with low-dose Cisplatin. The effects of Dicholoroacetic acid, 2-Deoxy-D-glucose and Metformin on cell cycle and recovery of Osteosarcoma cells were assessed. Their sensitivity to chemotherapy was also assessed when treated in combination with electroporation-delivered metabolic modulators.en
dc.description.sponsorshipBreakthrough Cancer Research; Teva Pharmaceutical Industries (fellowship research )en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationGill, K. S., Fernandes, P., Bird, B., Soden, D. M. and Forde, P. F. (2018) 'Combination of electroporation delivered metabolic modulators with low-dose chemotherapy in osteosarcoma', Oncotarget, 9(59), pp. 31473-31489. doi: 10.18632/oncotarget.25843en
dc.identifier.doi10.18632/oncotarget.25843
dc.identifier.endpage31489
dc.identifier.issn1949-2553
dc.identifier.issued59
dc.identifier.journaltitleOncotargeten
dc.identifier.startpage31473
dc.identifier.urihttps://hdl.handle.net/10468/6947
dc.identifier.volume9
dc.language.isoenen
dc.publisherImpact Journalsen
dc.relation.urihttp://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=25843&path[]=80841
dc.rights© 2018, the Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. https://creativecommons.org/licenses/by/3.0/en
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/
dc.subjectOsteosarcomaen
dc.subjectElectroporationen
dc.subjectMetabolic modulationen
dc.subjectCell cycleen
dc.subjectCombination treatmenten
dc.titleCombination of electroporation delivered metabolic modulators with low-dose chemotherapy in osteosarcomaen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Combination of electroporation delivered metabolic modulators.pdf
Size:
6.45 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Loading...
Thumbnail Image
Name:
Combination of electroporation delivered metabolic modulators with low-dose chemotherapy-1.pdf
Size:
580.52 KB
Format:
Adobe Portable Document Format
Description:
Supplemental File 1